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Parents’ responses to receiving sickle cell or cystic
fibrosis carrier results for their child following
newborn screening
Fiona Ulph1, Tim Cullinan2, Nadeem Qureshi3 and Joe Kai*,3
Universal newborn screening for sickle cell disorders and cystic fibrosis aims to enable the early identification and treatment of
affected babies. Screening can also identify infants who are healthy carriers, with carrier results being the commonest outcome
for parents and professionals to discuss in practice. However it is unclear what the effect will be on parents on being informed
of their baby’s carrier result. Semi-structured face-to-face interviews were conducted with a purposeful sample of 67 family
members (49 mothers, 16 fathers, 2 grandparents) of 51 infants identified by universal newborn screening as carriers of cystic
fibrosis (n¼27) and sickle cell (n¼24), across all health regions in England. Data were analysed by thematic analysis with
subsequent respondent validation. Untoward anxiety or distress among parents appeared influenced by how results were
conveyed, rather than the carrier result per se. Parents who had more prior awareness of carrier status or the possibility of a
carrier result assimilated the information more readily. Being left in an information vacuum while awaiting results, or before
seeing a professional, led some parents to fear that their child had a serious health condition. Parental distress and anxiety
appeared mostly transient, subsiding with understanding of carrier status and communication with a professional. Parents
regarded carrier results as valuable information and sought to share this with their families and to inform their children in the
future. However parents needed greater support after communication of results in considering and accessing cascade testing,
and negotiating further communication within their families.
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INTRODUCTION
Newborn bloodspot screening is regarded as a significant public
health achievement in the developed world.1 Newborn screening
(NBS) policies vary internationally in terms of diseases screened for,
with differing approaches to consent.1 For example, newborn
screening is usually mandatory in the US, whereas in Canada a
largely ‘opt-out’ policy requires testing for all newborns unless parents
decline testing. NBS for cystic fibrosis (CF) and sickle cell diseases
(SCD) was implemented nationally across the whole of England in
2007 but is offered to parents of all newborns using a voluntary
informed consent model to ‘opt in’ to screening.2 Screening guidelines
and training materials stress the central role that information
provision has in parents ability to consent.3,4 Yet, evidence suggests
several barriers to this communication including parents failing to
appreciate the personal relevance of screening information,5
information overload during pregnancy6 and conflicting familial or
existing personal knowledge.7 The challenge of creating antenatal
communication protocols which meet parents’ information needs,
provided when parents are able to assimilate the information and
appreciate the personal relevance is recognised.8
Although the rationale for informed consent is based on respecting
parents’ autonomy,9 information provision may influence how
parents respond to NBS results. In relation to metabolic disorders,
NBS carrier or false positive results can trigger anxiety if
misunderstood, or if parents with children undergoing further
testing related to false positive results are not provided with timely
and adequate information.10,11 Such anxiety has been linked to
impaired relationships with the baby11–13 and lasting effects of
stress during childhood.14 This suggests that earlier fears that
newborn PKU screening may trigger the vulnerable child syndrome
for some parents15,16 may have been realised. For these parents
multiple and/or specialist health professional consultations are often
needed to allay such anxiety.17 Research in the US has suggested that
inadequate preparation for NBS results can exacerbate anxiety and
shock for parents who are informed that their child is a genetic carrier
of cystic fibrosis or sickle cell18 and that the content of information
given can affect parents’ reactions.19 This paper reports a qualitative
exploration of the impact of receiving cystic fibrosis or sickle cell
carrier results on parents following screening of their newborns in
England, where the use of an informed consent model could
potentially reduce possible harms of disclosing carrier status.20–22
This study formed a part of wider cross-sectional research in the
practice, methods and experience of communication following
newborn screening across England.6
MATERIALS AND METHODS
Recruitment
Recruitment sites, and parents informed of their baby’s carrier results were
purposively sampled to ensure the wide range of differing methods of
communicating carrier status information in England were captured.21
Parents were recruited from across all nine health regions in England in
2008. Health professionals distributed study packs to parents who had received
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newborn carrier results. Parents who returned ‘consent to contact’ forms were
contacted by a researcher to discuss the study, and arrange an interview if
appropriate, with informed consent undertaken at interview. Parents who
returned the translation request form were contacted with a professional
interpreter and a three-way telephone conversation was held to discuss
participation. Following the interviews, parents were informed that they
would receive a research summary, and asked if they were willing to be
contacted again for discussion and validation of preliminary findings.
Data generation
Semi-structured interviews were conducted in participants’ homes, using
professional interpreters where necessary for non-English speakers. Parents
were encouraged to relate their experiences from when they were first aware
that their child was to be screened and interviews flexibly followed a topic
guide which was modified following initial interviews. Interviews were
recorded and transcribed verbatim in English. Interview transcripts translated
from other languages were checked by independent interpreters for accuracy
and equivalence of meaning.
Analysis and validation
Data generation and analysis were iterative, with each informing the other
using techniques derived from grounded theory. This was undertaken by field
researchers with health psychology and social science backgrounds, with the
wider investigating team (clinical primary care/genetics academics) contribut-
ing to development of themes from a multidisciplinary perspective. Data were
managed within NVivo software. Further theoretical sampling and data
collection sought deviant cases to extend and challenge the analysis until
saturation was achieved. This was followed by a respondent validation exercise
in which all participants were sent a summary of the findings, translated where
appropriate. Participants were then invited to participate in semi-structured
telephone interviews to comment on the findings, reflect further on their
experience and add any further views.
Ethical approval. An NHS multicentre research ethics committee (West
Midlands) granted ethical approval to the study.
RESULTS
Interviews were conducted with 67 family members of 51 infants
identified by newborn screening as carriers of CF (27) and SC (24).
Interviews were conducted with parents across all the nine health
regions of England, including high and low prevalence areas for sickle
cell disorders. Eight interviews were conducted with professional
interpreters (French¼ 3; Bengali¼ 3; Portuguese¼ 2). Further semi-
structured telephone interviews, for respondent validation, were
conducted with 17 parents, three to fourteen months after their
initial interview. Characteristics of participants and their infants are
summarised in Tables 1 and 2.
Parents in the sample experienced a wide range of methods of
communication of carrier results (see Supplementary Tables 3 and 4).
Four principal aspects of receiving a carrier result following
newborn screening which affected parents were developed from data
analysis: the impact of knowing the carrier result; effect of the process
of communication; cascade testing within the family; and sharing of
carrier information with extended family.
Impact of knowing carrier result
With the exception of one parent who was uncertain, all parents felt it
was important that they be informed of their child’s carrier result.
This was regarded as valuable new information about and for their
child, gained fortuitously.
I am happy to know it, because it didn’t involve any additional tests
you know which is always nice for a little baby and it’s, I think, it is
valid information.[y] I could even argue that there is a need to
know... (#33, mother of an SC carrier; low SC prevalence area).
Most parents were not concerned or distressed by the carrier result
per se. Most recognised that this was not ‘bad news’ and it had no
direct adverse effect on their child.
I don’t think [parents] should be upset about this, it is very
important not just for them, but for the child involved as well.
(#3, Mother of an SC carrier; high SC prevalence area.)
Table 1 Characteristics of parent respondentsa
N¼67 (%)
Ethnicity
White British 43 (64)
Black African/British/Caribbean 14 (21)
Bangladeshi 3 (4)
White European/Other 3 (4)
Mixed 3 (4)
Asian Thai 1 (1)
Employment status
Employed full time 33 (49)
Employed part time 12 (18)
Full-time parent 11 (16)
Full-time student 3 (4)
Full-time carer 1 (1)
Unemployed 1 (1)
Not indicated 6 (9)
Highest educational attainment
Degree or higher degree 22 (33)
NVQ, Diploma, A-level, HND or equivalent 17 (25)
GCSE or equivalent (school to 16 years) 14 (21)
None 1 (1)
Not indicated 13 (19)
Parent carrier status
Not tested 19 (28)
Tested – carrier SC 17 (25)
Tested – carrier CF 11 (16)
Tested – not carrier CF 11 (16)
Tested – not carrier SC 9 (13)
aIncludes two grandparents.
Table 2 Characteristics of newborn infants, N (%)
N¼51
Infant carrier characteristics
Carrier of CF 27 (53)
Carrier of SC/other haemoglobin variant 24 (47)
Gender
Female 24 (47)
Male 27 (53)
Family units
Mother lives with baby’s father 43 (84)
Mother lives with partner 1 (2)
Single parent household 7 (14)
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Some parents felt positively reassured when they heard that their
child was a carrier, particularly those parents awaiting the results of a
second IRT blood test for CF ), who had worried about their child
being affected by the condition. (The CF newborn screening protocol
in England aims to identify a maximum of children with CF, while
minimising carrier detection. This involves measuring immunoreac-
tive trypsinogen (IRT) levels to identify babies with levels exceeding
the 99.5 percentile, indicative of CF. Samples from newborns with
raised IRT levels undergo DNA analysis to establish if the child has
two mutations, and is therefore likely to have CF, or has one mutation
and is probably a carrier. Children with suspected CF are referred for
a clinical diagnosis. Those with one mutation, or an initial IRT499.9
percentile and no detected mutation, require a second bloodspot test
to verify if IRT is still elevated at 3–4 weeks when IRT levels are more
discriminatory. In those children with one mutation, where the IRT
remains elevated the likelihood of CF is regarded as high and triggers
clinical referral, whereas if not still elevated the likelihood of CF is low
and the child is regarded a healthy carrier.)
When they said she didn’t have it [affected with CF] I was ‘away’,
that was it, I’d closed down, that was fine [y] for me it was like ‘I
can switch off now’. (#37, Mother of a CF carrier.)
Some parents underlined how they felt identification of carriers,
and being informed of this, was helpful.
[y] people knowing that they’ve got this status is really important,
because there might be less people with the sickle cell disease in the
future for people having that knowledge. [y] hopefully the majority
will take it on board and think ‘I don’t want my child to be ill and so
therefore I’m going to be careful’ you know and that’s surely
important. (#35, Mother of an SC carrier; low prevalence area.)
When asked to reflect on the possibility that technology might
ensure that carriers were not identified via NBS, parents did not
support this:
If you stop telling people that they’re carriers, that’s got to be going in
the wrong direction because at least if you’re a carrier you know
before she has children hopefully they’ll talk about it and he’ll go and
get tested so they know what the likelihoody(#37, mother of a CF
carrier, first child).
Although most parents appeared to understand the ‘benign’
implications of their baby’s carrier status, a minority of parents (four
families, two of SC carriers, two of CF carriers) remained unduly
concerned about their child’s health after receiving results. They
expressed negative or ambivalent reactions to knowledge of their
child’s carrier result such as guilt or had prominent concerns about
the child’s health.
So I still worry and I just think ‘She’s still little, anything she gets now
could bring something else out’ you know you’ve still got it in your
head even though it’s been cleared up for you, you still worry a little
bit that how can something genetically just be as black and white as
that? (#40 mother CF carrier).
Effect of process of communication
Some parents experienced distress or anxiety linked to their experi-
ence of newborn screening, in particular for CF (12/27 CF carrier
families, 2/24 SC carrier families). This ranged from mild, short-lived
anxiety, to more profound distress. This could manifest in reducing
the child’s interaction with others, arguments between couples,
alteration of life plans and an inability to conduct tasks of daily
living such as going to work or socialising. Most parents who reported
such distress reflected that how carrier result information had been
communicated to them had been the cause ‘y to some extent these
things are often not so much about what you tell me but how you tell
me’ (#55, mother of an SC carrier). This was particularly salient in
relation to communication around the time of the repeat blood
sample in CF screening. (The CF newborn screening protocol in
England aims to identify a maximum of children with CF, while
minimising carrier detection. This involves measuring immunoreac-
tive trypsinogen (IRT) levels to identify babies with levels exceeding
the 99.5 percentile, indicative of CF. Samples from newborns with
raised IRT levels undergo DNA analysis to establish if the child has
two mutations, and is therefore likely to have CF, or has one mutation
and is probably a carrier. Children with suspected CF are referred for
a clinical diagnosis. Those with one mutation, or an initial IRT499.9
percentile and no detected mutation, require a second bloodspot test
to verify if IRT is still elevated at 3–4 weeks when IRT levels are more
discriminatory. In those children with one mutation, where the IRT
remains elevated the likelihood of CF is regarded as high and triggers
clinical referral, whereas if not still elevated the likelihood of CF is low
and the child is regarded a healthy carrier.)
Mother: I really wanted to get across just how really bad the process
was for us, but then the relief of eventually getting the results and the
relief of knowing that it wasn’t cystic fibrosis and the problems of
looking to know that we’re a carrier and that our baby’s going to be
absolutely fine really. It was more the process of the actual results you
know I think I probably had the hardest time dealing with it because
it seemed to be never-ending.
Father: It’s the length of time, the lack of communication, lack of
knowledge. (#50, Parents of a CF carrier; told would hear
screening result within 4 weeks, but contacted 6 weeks later,
on a Sunday, by a midwife saying ‘problem with heel prick test’
and their child retested that day at a weekend. Told poor
sample, with not enough blood. Second sample was then lost.)
Poor communication that failed to anticipate or address concerns
appeared to have a major impact at this time. This included examples
of parents of carriers who had become concerned that their child was
chronically ill or perceived their child as fragile and so limited their
interaction with others.
You think your daughter’s seriously ill and could die and will need
physiotherapy all right through her life; will never be able to integrate
properly at school and you’re thinking ‘Well, what’s going to happen
career-wise?’ because you plan that she’ll go to full-time nursery and
actually she won’t be able to do that, so maybe we’ll have to give up
work, [y] so your mind just goes on, and on, and on. (#4, Father
of a CF carrier; parents had been told that if they heard nothing
in 2 weeks then ‘everything was ok’; in the 4th week, got a
phone message stating that there was a ’problem with heel prick
test’. When parents called the contact number, they were told
the CF test was positive and that it appeared their daughter may
have CF, but the service was unable to give parents further
information at that stage.)
The data suggested that if parents were left in limbo regarding their
child’s result at any stage, it could lead to rumination and catastrophic
thinking. Others simply felt unable to deal with people’s enquiries
about the results while waiting:
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[...] I mean it literally reached a point where I said ‘I don’t want to
see anybody, I want you to leave [name of child] and me on our own
and not have toy. ’ Because every time you’re speaking to someone
as well, that did know our situation, it would always come back to
‘Why haven’t you heard anything?’ and they were questions that we
couldn’t answer so it became easier for me to just not deal with
anybody at all. I would probably say it was probably the worst
moment of my entire lifey (#50, mother of CF carrier).
During this period, some parents had felt depressed, been unable to
sleep or concentrate at work, or described a negative impact on
personal relationships.
We had two massive blow ups at each other and it was a case of
me...feeling left out that is what it was about really. [y] you do feel
that isolated, it’s unbelievable. (#41, Father of CF carrier; parents
initially told ‘bad news’ their child is a carrier, but may possibly
have CF. The next day, at hospital, told child has CF but before
diagnostic sweat test conducted. Subsequently, two sweat tests
were negative for a diagnosis of CF.)
Fathers also appeared to struggle because at the time of waiting for
the second IRTresult for CF many were back at work (The CF newborn
screening protocol in England aims to identify a maximum of children
with CF, while minimising carrier detection. This involves measuring
immunoreactive trypsinogen (IRT) levels to identify babies with levels
exceeding the 99.5 percentile, indicative of CF. Samples from newborns
with raised IRT levels undergo DNA analysis to establish if the child has
two mutations, and is therefore likely to have CF, or has one mutation
and is probably a carrier. Children with suspected CF are referred for a
clinical diagnosis. Those with one mutation, or an initial IRT 499.9
percentile and no detected mutation, require a second bloodspot test to
verify if IRT is still elevated at 3–4 weeks when IRT levels are more
discriminatory. In those children with one mutation, where the IRT
remains elevated the likelihood of CF is regarded as high and triggers
clinical referral, whereas if not still elevated the likelihood of CF is low
and the child is regarded a healthy carrier.):
I still went to work but I found myself hiding in my office more often
than I normally would do. [y] I found it very difficult to manage
really just the day to day disciplining and just try toy. I don’t know
just try to keep it straight really. (#50, Father of CF carrier.)
However further explanation and communication of results in
discussion with a well-informed professional appeared to have allayed
these concerns in most parents.
Until I actually went to the [genetics centre] and that doctor
probably explained it a lot more clearly, and to me it [feeling of
guilt]sort of dampened down and from then on.. I could feel myself
much more relieved by the whole sort of thing. (#40, Mother of CF
carrier; told needed second screening sample but was pre-
warned this is common and nothing to be concerned about.
Was initially told child could be carrier, but not provided with
further information at that stage by professional, so she sought
information on internet and became upset)
Only three of 38 parents of CF carriers were aware of their own CF
carrier status before newborn screening of their child. In contrast, 21
of 29 parents of SC carriers were already familiar with their own
carrier status through previous or antenatal testing and for these
parents experience of distress appeared less common. Prior knowledge
of personal carrier status appeared to help parents assimilate the
information about their child ‘she is just like me, she is AC’ (#3,
mother of SC carrier).
Parents who had reported considerable distress regarding NBS in
their original interview later felt, during respondent validation, that
they had now come to terms with the experience, and continuing
anxiety was rare. This was usually as a result of subsequent direct
communication with a health professional. One participant reported
continuing occasional concerns when their child, a carrier of CF,
became unwell with a cold.
Considering ‘cascade’ testing within the family
For many parents, knowing their child’s carrier status led them to
question, and consider establishing, which parent was a carrier if this
was not already known; and to consider the carrier status of their
other children. In relation to parents’ own carrier status, the issue of
non-paternity was tangentially raised in three cases: parents’ carrier
status was seen to offer reassurance of paternity in two cases and in
one case an oblique reference was made to the child’s inheritance of a
gene ‘skipping a generation’. Some parents had begun to worry if their
other children had not been tested and were approaching reproduc-
tive age, or were from previous relationships, and how they might
broach this with their children.
It’s just lingering because I have got two children from my previous
marriage and if I am the carrier then it would be nice to inform them
and tell them, you know, what would they like to do about it? (#5,
Father of a CF carrier.)
While some parents felt unable to ‘move on’ until testing had
occurred for themselves or been offered to other relevant family
members, others varied in their desire to do so, and how it may affect
their future decisions.
I am of the opinion of I don’t want to [know] whereas you [referring
to father] are more inclined that you do want to know. (#19,
Mother of a CF carrier.)
Some parents, however, had experienced difficulties in accessing
cascade testing.
My other concern was before my 3½ year old was born they weren’t
specifically tested for this [before universal newborn SC/CF screen-
ing] so I wanted to know how I got him tested and [the health
visitor] had no idea. (#13, Mother of an SC carrier; sibling
subsequently tested.)
Others were concerned that despite their newborn being identified
as a carrier, they were unable to access cascade testing for their other
children until they were older (and had reached the age of consent
themselves), encountering no flexibility in the system:
When we told her [sibling of newborn carrier] we said, you know,
they’ve said you need to have this test when you’re 16 and she just
turned round and went ‘Why can’t I have it now?’ (#12, Mother of
a newborn CF carrier, older sibling aged 10 years.)
This was a particular source of parents’ frustration:
ythey won’t let me have her tested. The argument is she has to wait
until she is 16 and classed as an adult or whatever it was [y] but I
feel that we are her parents and should be able to be responsible (#64,
mother of CF carrier, sibling not tested).
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Sharing carrier information with extended family
Most respondents felt a responsibility to share their newborn’s carrier
status information with their extended families, but some struggled
with knowing who to tell or how to raise the issue, or were concerned
about creating anxiety.
y my cousin’s girlfriend was pregnant, and [my partner] was
saying ‘You should tell them about the cystic fibrosis thing’ and I was
thinking ‘I shouldn’t tell them about the cystic fibrosis thing because
they’ve got 9 months of worry and then for them to think the baby
will have an abnormality when its born’ and I don’t think that’s fair.
(#37, Father of a CF carrier.)
Others had no concerns about telling family members and
discussed how their extended families appeared to respond positively
to the news, by showing interest, getting tested and understanding
that carrier status had minimal health implications.
[The whole family came] round for Sunday lunch, we’ll sit round
the table, we’ll discuss it. And it was really nice you know; you don’t
have to worry. (#12, Mother of a CF carrier.)
However respondents also reported negative reactions from their
families including relatives avoiding related conversations; and
refusing to believe the information in a context of stigma and
ignorance about the conditions.
..talked to my mother about it so many times, she doesn’t want to
listen, it’s like [y] she has turned a blind eye to it and I said to her
that you have to get all my younger sisters to have them tested and
she has turned a blind eye to it and so I have stopped talking about
it. (#3, Mother of an SC carrier.)
Family members also distanced themselves from the issue by
blaming the other side of the family. When this occurred between
parents it could exacerbate previously fractious relationships.
[the wider family] were just looking at it as a negative, do you know
what I mean? They were looking at it as if something that y like
really ashamed and it was like ‘Oh none of us are affected’. (#37,
Mother of a CF carrier.)
Some families did not wish to pursue cascade testing creating
ambivalence among parents of carriers who did not feel it
appropriate to dictate to others, but who also had concerns
that they should be more proactive to ensure this occurred.
The lack of family members’ engagement in testing could cause
some distress.
it came out that it was his family, but you know I have told him, but
none of his family want to be tested even though his niece is trying to
have a baby andy They don’t really, yeah I begged her but she is not
in their family and they don’t want to be tested for it you know. (#22,
Mother of a CF carrier.)
Some felt health professionals should offer advice on how to
discuss the issue or become involved in such communication. Where
this had occurred, it was appreciated:
[the health professional] was trying to be really helpful she e-mailed
[husbands’ name] the letter [containing the carrier information] so
that he could get it to his family before and then she posted it out...
(#58, mother of CF carrier).
DISCUSSION
This study suggests that disclosure of CF or SC carrier results
following universal newborn screening can have significant effects
for parents and wider family members. For many parents, although
being informed of their child’s carrier status was positive, and this
information was valued, there was considerable anxiety and distress
following the initial communication of results. However, subse-
quently, parents appeared capable of understanding and assimilating
this information into their lives. This suggests that concerns about
provoking a vulnerable child syndrome15 may be avoided given
appropriate communication and support.
The process of communicating the result, including messages from
health professionals which contained insufficient information, or
waiting for information, was not benign and was commonly reported
as a key source of any distress, impacting social engagement. This
echoes work conducted in the US and Australia in relation to CF
newborn screening.22,23 Our data also suggest sometimes wider
detrimental impact on employment, parental relationships which
may already be under some strain with the arrival of a newborn, and
in particular, on the extended family. This adds to evidence that
parents’ information needs may not have been met in a timely or
adequate manner and that parents may find newborn screening
distressing.14,24–29 Ensuring that parents are not left in an information
vacuum at any stage of the screening process may minimise the risk of
harmful effects from screening.
Although some parents required additional specialist services, once
carrier results were understood this knowledge did not appear to have
a lasting negative effect on most parents in this study and was highly
valued – as has been found previously in other countries.20,22,30,31
Parents in the current study appear to underline this by viewing any
change to protocols to not identify carriers as a backwards step. These
findings can inform the ongoing debate about whether to identify
carriers or inform parents,32 and conflicting findings regarding the
impact of doing so.13,23,30 The results also address an identified gap in
the evidence regarding communicating SC carrier rather than CF
carrier results33 and whether it is true that the lack of repeat testing in
SC screening means there is less anxiety.20 Although most of the
distress in CF screening centred around repeat testing in the current
study, we still found concerns and anxiety in those within the SC
sample. The issue of involving fathers more in antenatal and neonatal
screening has been raised previously34 and the current data highlight
the disempowering effects on fathers when communication of results
occurs solely with the mother. Although referred to, the issue of non-
paternity being revealed by newborn carrier results did not feature
prominently with parents interviewed in this study, though it is
recognised that they were providing ‘public’ accounts of their
experiences to researchers.
The current findings start to address the paucity of data regarding
how and what parents are told regarding NBS results.35 In doing so,
they underline that communication of information and support
following newborn screening is required beyond the infant period
to facilitate access to cascade testing and support the challenges of
familial communication. The issue of families avoiding
communication about carrier information, and inferring blame or
stigma has been discussed in relation to antenatal screening for sickle
cell,34 as have the difficulties in working out who to tell and when.34
The current study highlights the same for newborn screening and the
current lack of a defined role for any specific professional to provide
such support. Given the period of time it may take for families
to adapt to this information, this role might, for example, be
developed in primary care, as part of continuing care with families,
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or within-community-based genetic counselling. Our results also
highlight that parents’ concerns regarding communication processes
for receiving carrier results are nevertheless similar to parents who
receive results that their child is affected by the condition.35 Moreover,
we have found that these concerns, previously identified when
screening is mandatory and information provision is assumed to be
minimal, can also occur in a newborn screening programme that
adopts an informed consent model.
Strengths and limitations
A range of methods were used to enhance rigour, and the relevance of
study results including purposeful sampling, iterative data generation,
analysis to saturation, involving researchers from several disciplines
and use of respondent validation.36 The sample is described in some
detail including, for example, information on parents’ own carrier
status and social backgrounds, and the diversity of provider methods
of communication of carrier results that they experienced in practice.
This may aid assessment of the transferability and relevance of the
findings beyond the immediate study context.
The sample is substantial when compared with previous qualitative
work with parents of SC carrier,37 CF carriers22,30,38,39 or both types
of carrier.40 Those recruited also represent a significant proportion of
the very small number of newborn CF carriers identified annually in
England. Within the practical constraints of study recruitment and
duration, the research has successfully included parents’ experiences
across all health regions of England following the introduction of
universal newborn screening for SC and CF. The lack of fathers’
perspectives in newborn screening research has caused concern,41 but
the current study included fathers wherever possible, ultimately
forming a quarter of the sample.
Although active inclusion of those willing to articulate their
experiences is key to qualitative enquiry, we recognise that the
experiences and views of study participants may not be typical of
all receiving carrier results following newborn screening. Our sample
was relatively well-educated, a feature similar to other studies
concerning CF screening in particular13,42 and appeared relatively
genetically literate. Their experiences may however serve to reinforce
the identified needs to improve information delivery and continuing
support for the wide range of parents who experience newborn
screening.
Further research should investigate how best to prepare parents for
NBS before results as this appears to affect the impact of results on
parents; and examine parents’ attitudes towards, access to and
experience of cascade testing and its impact on later reproductive
decisions. In parallel, work is needed to develop and evaluate methods
to support cascade testing and communication of carrier information
with children and families; and capture further experience of families
over time to enable greater understanding of longer-term benefits or
harm of newborn carrier identification.
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